Both in Biotechnology
Neurocrine Biosciences vs Exelixis
Over the past year NBIX returned −1.4% and EXEL returned +44.6%; their daily moves had a correlation of 0.44.
NBIX −1.4% EXEL +44.6%Growth of $1, one year, split-adjusted
| Metric | NBIX | EXEL |
|---|---|---|
| Price | $138.35 | $58.65 |
| Market cap | $14.06B | $14.53B |
| Today | −1.49% | +0.48% |
| 1 month | −10.2% | +7.7% |
| 6 months | +7.5% | +39.8% |
| Year to date | −2.5% | +33.8% |
| 1 year | −2.6% | +50.2% |
| Revenue growth (YoY) | +39.5% | +10.6% |
| Gross margin | 97.6% | 96.7% |
| Net margin | 15.1% | 33.7% |
| P/E (TTM) | 19.9× | 16.9× |
| Price / sales | 4.2× | 6.0× |
| Net cash | $389.8M | $839.4M |
| Dividend yield | — | — |
| Volatility (60d) | 34.4% | 34.5% |
| Short % of float | 5.1% | 10.8% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).